Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 91 clinical trials
Neoadjuvant Endocrine Therapy Palbociclib Avelumab in Estrogen Receptor Positive Breast Cancer

Eligible patients with estrogen receptor positive breast cancer will undergo a biopsy and be randomized to receive endocrine therapy (ET) versus endocrine therapy with palbociclib (PET) in a 1:2

tamoxifen
estrogen
letrozole
mammogram
breast surgery
  • 3 views
  • 03 Mar, 2021
  • 2 locations
Locoregional Treatment and Palbociclib in de Novo Treatment Naive Stage IV ER+ HER2- Breast Cancer Patients

Approximately 3.5% to 6% of newly diagnosed breast cancer patients are stage IV metastatic. De novo metastatic breast cancer accounts for 20% to 25% of these cases. Despite a decrease in mortality in Europe and North America due to early detection and access to treatment, breast cancer remains the 2 …

estrogen
hormone therapy
luminal
metastatic breast cancer
HER2
  • 0 views
  • 25 Jan, 2021
  • 34 locations
A Study of the Use of Text Message Reminders to Take Palbociclib

The purpose of this study is to find out whether it is feasible (acceptable to participants) to use a smartphone app to send text message reminders to take palbociclib, and whether these

breast carcinoma
fulvestrant
palbociclib
  • 8 views
  • 27 Jan, 2021
  • 7 locations
Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy

PROMETEO II is a single-arm window of opportunity trial to evaluate biologic and anti-proliferative effects of palbociclib and letrozole in HR+/HER2-negative operable breast cancer (BC) patients

epirubicin
paclitaxel
anthracyclines
HER2
doxorubicin
  • 2 views
  • 25 Jan, 2021
  • 5 locations
Palbociclib and Sorafenib Decitabine or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

This phase I trial studies the side effects and best dose of palbociclib when given alone and in combination with sorafenib, decitabine, or dexamethasone in treating patients with leukemia that

hydroxyurea
decitabine
ejection fraction
  • 84 views
  • 28 Jan, 2021
  • 2 locations
Anastrozole Palbociclib Trastuzumab and Pertuzumab in Her-positive Her2-positive Metastatic Breast

This is a multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab is proposed as first-line therapy in metastatic hormone receptor-positive, HER2-positive breast

tamoxifen
stage iv breast cancer
core needle biopsy
pertuzumab
her2/neu-positive breast cancer
  • 38 views
  • 24 Jan, 2021
  • 4 locations
Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma

of p16, loss of Rb and p53 functions. A novel therapy for HPV-negative SCCHN is clearly an unmet medical need. Palbociclib (PD 0332991) is an orally active, highly selective inhibitor of the

dental caries
mouth cancer
definitive treatment
squamous cell carcinoma
squamous cell carcinoma of head and neck
  • 82 views
  • 25 Jan, 2021
  • 1 location
Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

PATRICIA is a phase II, open-label, multicentre, Simon's two-stage-design study of the combination of palbociclib plus trastuzumab, with or without letrozole, in post-menopausal patients with

tamoxifen
breast adenocarcinoma
lapatinib
hormone therapy
trastuzumab
  • 15 views
  • 25 Jan, 2021
  • 23 locations
Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer

This is an open-label, pilot study designed to evaluate the safety and feasibility of combining anastrozole and palbociclib in the following two cohorts: Cohort A) as first-line therapy and

  • 14 views
  • 27 Jan, 2021
  • 1 location
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

/6 inhibitor palbociclib.

solid tumour
metastatic pancreatic cancer
measurable disease
neutrophil count
  • 63 views
  • 23 Jan, 2021
  • 1 location